About the Authors
- José Ángel Hernández
-
Contributed equally to this work with: José Ángel Hernández, María Hernández-Sánchez
Affiliation Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain
- María Hernández-Sánchez
-
Contributed equally to this work with: José Ángel Hernández, María Hernández-Sánchez
Affiliation IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain
- Ana Eugenia Rodríguez-Vicente
-
Affiliation IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain
- Vera Grossmann
-
Affiliation MLL Munich, Germany
- Rosa Collado
-
Affiliation Hematology Department, Hospital General, Valencia, Spain
- Cecilia Heras
-
Affiliation Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain
- Anna Puiggros
-
Affiliation Pathology Department, Hospital del Mar, Barcelona, Spain
- Ana África Martín
-
Affiliation Hematology Department, Hospital Universitario, Salamanca, Spain
- Noemí Puig
-
Affiliation Hematology Department, Hospital Universitario, Salamanca, Spain
- Rocío Benito
-
Affiliation IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain
- Cristina Robledo
-
Affiliation IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain
- Julio Delgado
-
Affiliation Hematology Department, Hospital Clinic i Provincial, Barcelona, Spain
- Teresa González
-
Affiliation Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
- José Antonio Queizán
-
Affiliation Hematology Department, Hospital General, Segovia, Spain
- Josefina Galende
-
Affiliation Hematology Department, Hospital del Bierzo, Ponferrada, León, Spain
- Ignacio de la Fuente
-
Affiliation Hematology Department, Hospital Universitario Río Hortega, Valladolid, Spain
- Guillermo Martín-Núñez
-
Affiliation Hematology Department, Hospital Virgen del Puerto, Plasencia, Cáceres, Spain
- José María Alonso
-
Affiliation Hematology Department, Hospital Río Carrión, Palencia, Spain
- Pau Abrisqueta
-
Affiliation Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain
- Elisa Luño
-
Affiliation Hematology Department, Hospital Central de Asturias, Oviedo, Spain
- Isabel Marugán
-
Affiliation Hematology Department, Hospital Clínico, Valencia, Spain
- Isabel González-Gascón
-
Affiliation Hematology Department, Hospital Universitario Infanta Leonor, Universidad Complutense de Madrid, Madrid, Spain
- Francesc Bosch
-
Affiliation Hematology Department, Hospital Vall d'Hebron, Barcelona, Spain
- Alexander Kohlmann
-
Affiliations MLL Munich, Germany, AstraZeneca, Personalized Healthcare and Biomarkers, Innovative Medicines, Macclesfield, United Kingdom
- Marcos González
-
Affiliations IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain, Hematology Department, Hospital Universitario, Salamanca, Spain
- Blanca Espinet
-
Affiliation Pathology Department, Hospital del Mar, Barcelona, Spain
- Jesús María Hernández-Rivas
-
* E-mail: jmhr@usal.es
Affiliations IBSAL, IBMCC, Centro de Investigación del Cáncer, Universidad de Salamanca,CSIC, Hospital Universitario de Salamanca, Spain, Hematology Department, Hospital Universitario, Salamanca, Spain, Department of Medicine, Universidad de Salamanca, Spain
- Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfática Crónica (GELLC)
-
¶Membership of the DataBase of CLL of Grupo Cooperativo Español de Citogenética Hematológica (GCECGH) and Grupo Español de Leucemia Linfocítica Crónica (GELLC) is provided in the Acknowledgments.
Competing Interests
The authors have declared that no competing interests exist. Oligonucleotide primer plates for amplicon deep-sequencing were provided by Roche Diagnostics, Penzberg, Germany, as part of the IRON-II study. VG and AK were employed by MLL Munich Leukemia Laboratory and AK is employed by AstraZeneca. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: JAH MHS AERV JMHR. Performed the experiments: MHS AERV CR RB. Analyzed the data: JAH MHS AERV CR RB. Contributed reagents/materials/analysis tools: VG AK RC CH AP AAM NP JD TG JAQ JG IF GMN JMA PA EL IM IG MG. Wrote the paper: JAH MHS AERV CR RB VG FB BE MG JMHR.